Evidence map›Paper›PMID 36844603›Full record

ArticleACS omega2023

Design, Synthesis, and Biological Evaluation of the First Radio-Metalated Neurotensin Analogue Targeting Neurotensin Receptor 2.

Sacha Bodin, Santo Previti, Emmanuelle Jestin, Delphine Vimont, Imade Ait-Arsa, Frédéric Lamare, Emmanuelle Rémond, Elif Hindié, Florine Cavelier, Clément Morgat

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS omega, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Design and Synthesis ofChemMedChem · 2025
    Article
  2. Neurotensin and Its Involvement in Female Hormone-Sensitive Cancers.International journal of molecular sciences · 2024
    Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Sacha BodinDepartment of Nuclear Medicine, University Hospital of Bordeaux, 33076 Bordeaux, France.ORCID https://orcid.org/0000-0001-7331-8536
Santo PrevitiInstitut des Biomolécules Max Mousseron, IBMM, UMR 5247, CNRS, Université de Montpellier, ENSCM, 1919 route de Mende, 34293 Montpellier cedex 5, France.
Emmanuelle JestinCyclotron Réunion Océan Indien CYROI, 2 rue Maxime Rivière, 97490 Sainte Clotilde, France.
Delphine VimontUniversity of Bordeaux, CNRS, EPHE, INCIA, UMR 5287, Bordeaux F-33000, France.
Imade Ait-ArsaCyclotron Réunion Océan Indien CYROI, 2 rue Maxime Rivière, 97490 Sainte Clotilde, France.
Frédéric LamareDepartment of Nuclear Medicine, University Hospital of Bordeaux, 33076 Bordeaux, France.
Emmanuelle RémondInstitut des Biomolécules Max Mousseron, IBMM, UMR 5247, CNRS, Université de Montpellier, ENSCM, 1919 route de Mende, 34293 Montpellier cedex 5, France.ORCID https://orcid.org/0000-0002-3201-4365
Elif HindiéDepartment of Nuclear Medicine, University Hospital of Bordeaux, 33076 Bordeaux, France.
Florine CavelierInstitut des Biomolécules Max Mousseron, IBMM, UMR 5247, CNRS, Université de Montpellier, ENSCM, 1919 route de Mende, 34293 Montpellier cedex 5, France.ORCID https://orcid.org/0000-0001-5308-6416
Clément MorgatDepartment of Nuclear Medicine, University Hospital of Bordeaux, 33076 Bordeaux, France.ORCID https://orcid.org/0000-0002-9432-9223

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Neurotensin receptor 2 (NTS

Identifiers

PMID36844603
PMCPMC9948202

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.